Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal latanoprost
- Development stage
- Phase 2
- Lead developer
- Peregrine Ophthalmic
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Subconjunctival
01
Overview
Liposomal latanoprost is a sustained-release formulation of latanoprost, a prostaglandin F2α analog used to treat glaucoma and ocular hypertension. The drug is encapsulated in liposomes (phospholipid vesicles) that allow for extended release over time. This formulation significantly increases ocular bioavailability and extends the duration of IOP-lowering effects compared to conventional latanoprost eye drops. When administered via subconjunctival injection, it can maintain therapeutic effects for up to 50 days, compared to daily administration required for traditional eye drops.
- Brand names
- LIPOLAT
- Other names
- latanoprost extended releaselatanoprost liposomal
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on liposomal latanoprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal latanoprost.